Background: The current study was performed to compare the clinical outcomes and toxicity in patients treated with postoperative chemoradiotherapy for gastric cancer using intensity-modulated radiotherapy (IMRT) versus 3-dimensional conformal radiotherapy (3D CRT).
Methods: Fifty-seven patients with gastric or gastroesophageal junction cancer were treated postoperatively: 26 with 3D CRT and 31 with IMRT. Concurrent chemotherapy was capecitabine (n=31), 5-fluorouracil (5-FU) (n=25), or none (n=1). The median radiation dose was 45 Gy. Dose volume histogram parameters for kidney and liver were compared between treatment groups.
Results: The 2-year overall survival rates for 3D CRT versus IMRT were 51% and 65%, respectively (P=.5). Four locoregional failures occurred each in the 3D CRT (15%) and the IMRT (13%) patients. Grade>or=2 acute gastrointestinal toxicity was found to be similar between the 3D CRT and IMRT patients (61.5% vs 61.2%, respectively) but more treatment breaks were needed (3 vs 0, respectively). The median serum creatinine from before radiotherapy to most recent creatinine was unchanged in the IMRT group (0.80 mg/dL) but increased in the 3D CRT group from 0.80 mg/dL to 1.0 mg/dL (P=.02). The median kidney mean dose was higher in the IMRT versus the 3D CRT group (13.9 Gy vs 11.1 Gy; P=.05). The median kidney V20 was lower for the IMRT versus the 3D CRT group (17.5% vs 22%; P=.17). The median liver mean dose for IMRT and 3D CRT was 13.6 Gy and 18.6 Gy, respectively (P=.19). The median liver V30 was 16.1% and 28%, respectively (P<.001).
Conclusions: Adjuvant chemoradiotherapy was well tolerated. IMRT was found to provide sparing to the liver and possibly renal function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.25246 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Outcomes and Toxicity in Patients With Esophageal Cancer After Trimodality Therapy With Step-and-Shoot Intensity-Modulated Radiation Therapy Versus Volumetric Modulated Arc Therapy: The MD Anderson Experience.
Clin Oncol (R Coll Radiol)
October 2024
Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Aims: To evaluate outcomes and toxicity after intensity-modulated radiation therapy given as step-and-shoot (SS) or volumetric modulated arc therapy (VMAT) for patients with locally advanced esophageal cancer treated with trimodality therapy (i.e. neoadjuvant concurrent chemoradiation therapy followed by surgery).
View Article and Find Full Text PDFTreating early-stage centrally-located non-small cell lung cancer with DCAT-SBRT in centers lacking the VMAT technique: a comprehensive study.
Front Oncol
December 2024
School of Nuclear Science and Engineering, East China University of Technology, Nanchang, Jiangxi, China.
Background: Volumetric-modulated arc therapy (VMAT) may have the highest overall performance for stereotactic body radiotherapy (SBRT) treatment of inoperable early-stage NSCLC. However, in centers lacking the VMAT technique, the dynamic conformal arc therapy (DCAT) technique is potentially the best option for small and rounded NSCLC-SBRT. Therefore, we will comprehensively analyze the advantages of the DCAT versus the other techniques except VMAT in terms of dosimetry, plan complexity, delivery time, γ-passing rates and the interplay effect.
View Article and Find Full Text PDFBenefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis.
Adv Radiat Oncol
January 2025
International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
Purpose: Oral mucositis (OM) is a debilitating side effect of cisplatin and intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer. The phase 3 ROMAN trial showed avasopasem manganese (AVA) significantly decreased individual endpoints of incidence and duration of severe oral mucositis (SOM, World Health Organization [WHO] grade 3-4), with nominal decrease in severity (WHO grade 4) and significant increase in the delay in onset of SOM. We sought to determine the Net Treatment Benefit (NTB) of AVA versus placebo (PBO) using the generalized pairwise comparisons (GPC) method.
View Article and Find Full Text PDFEfficacies of different postoperative radiotherapy techniques in patients with N2 non-small cell lung cancer: a meta-analysis.
Am J Transl Res
November 2024
Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine, Hebei University of Chinese Medicine Shijiazhuang 050011, Hebei, China.
Background: With clinical trials on the use of different modern precise radiotherapy techniques in the setting of postoperative radiotherapy (PORT) in N2 non-small cell lung cancer (NSCLC) accumulating, an updated meta-analysis was performed.
Methods: A literature search identified studies that investigated PORT versus non-PORT in N2 NSCLC patients. Overall survival (OS) and locoregional recurrence (LR) were employed.
Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario.
Clin Transl Radiat Oncol
January 2025
Department of Oncology, Queen's University, Kingston, Ontario, Canada.
Purpose: Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease, with a spectrum of anatomic extent, health status, and treatment approaches. Receipt of treatment and its intent should be independent of health system factors where care quality is optimal. We investigated the degree that modifiable health system factors are associated with receipt of treatment and treatment intent in stage III NSCLC in a large, universal health system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!